Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) – Analysts at SunTrust Banks dropped their FY2019 EPS estimates for shares of Bellicum Pharmaceuticals in a report issued on Sunday, December 2nd. SunTrust Banks analyst P. Lawson now anticipates that the biopharmaceutical company will post earnings of ($2.26) per share for the year, down from their previous estimate of ($2.04). SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ FY2020 earnings at ($2.04) EPS, FY2021 earnings at ($1.37) EPS and FY2022 earnings at ($0.35) EPS.
BLCM has been the topic of several other research reports. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Friday, November 9th. BidaskClub cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 28th. ValuEngine upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. Finally, Citigroup decreased their price objective on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $13.42.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.03. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.07 million.
In other Bellicum Pharmaceuticals news, Director Jon P. Stonehouse acquired 10,000 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were acquired at an average price of $4.56 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $45,600. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.84% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of BLCM. Vanguard Group Inc. boosted its holdings in Bellicum Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock valued at $11,999,000 after acquiring an additional 23,410 shares during the last quarter. Jefferies Group LLC boosted its holdings in Bellicum Pharmaceuticals by 117.9% in the third quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 25,325 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Bellicum Pharmaceuticals in the third quarter valued at $110,000. JPMorgan Chase & Co. boosted its holdings in Bellicum Pharmaceuticals by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 3,874,395 shares of the biopharmaceutical company’s stock valued at $23,866,000 after acquiring an additional 300,816 shares during the last quarter. Finally, Bridgeway Capital Management Inc. boosted its holdings in Bellicum Pharmaceuticals by 202.0% in the third quarter. Bridgeway Capital Management Inc. now owns 149,500 shares of the biopharmaceutical company’s stock valued at $921,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 56.13% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.